Technical Articles

The KRAS gene is one of the most common oncogenes in human tumors, frequently mutated in various solid tumors such as pancreatic cancer, colorectal cancer, and lung cancer.

The KRAS gene is one of the most commonly mutated oncogenes in lung cancer, discovered over two decades earlier than the EGFR gene. However, compared to the rapid development of EGFR-targeted therapies, targeted treatments for KRAS-mutated non-small cell lung cancer have long lagged behind.

The KRAS gene, one of the first discovered human oncogenes, is frequently mutated in various malignancies such as pancreatic cancer, colorectal cancer, and lung cancer, driving tumor initiation and progression.

The RAS gene family is the most widely mutated oncogene in tumors, accounting for approximately 20% to 30% of all tumor mutations, and includes three subtypes: KRAS, HRAS, and NRAS.

The RAS gene family is the most common oncogene in human cancers, encoding proteins that act as critical molecular switches regulating cell proliferation and survival signaling pathways.